Zacks Investment Research upgraded shares of Krystal Biotech (NASDAQ:KRYS) from a hold rating to a buy rating in a research report released on Tuesday morning. They currently have $18.00 price target on the stock.
According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “
A number of other equities research analysts have also recently issued reports on the company. HC Wainwright initiated coverage on Krystal Biotech in a report on Monday, September 24th. They set a buy rating and a $32.00 price objective for the company. Cantor Fitzgerald initiated coverage on Krystal Biotech in a report on Monday, September 10th. They set an overweight rating and a $28.00 price objective for the company. William Blair initiated coverage on Krystal Biotech in a report on Monday, August 6th. They set a buy rating for the company. ValuEngine upgraded Krystal Biotech from a hold rating to a buy rating in a report on Friday, September 21st. Finally, Chardan Capital restated a buy rating and set a $35.00 price objective on shares of Krystal Biotech in a report on Monday, August 6th. Seven research analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and an average target price of $30.20.
Shares of NASDAQ:KRYS opened at $16.14 on Tuesday. Krystal Biotech has a 12-month low of $8.03 and a 12-month high of $21.17. The company has a market cap of $182.02 million and a PE ratio of -10.91.
Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, August 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.12. On average, equities research analysts expect that Krystal Biotech will post -1.01 EPS for the current year.
An institutional investor recently raised its position in Krystal Biotech stock. Acadian Asset Management LLC increased its holdings in Krystal Biotech Inc (NASDAQ:KRYS) by 552.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,202 shares of the company’s stock after buying an additional 10,331 shares during the period. Acadian Asset Management LLC owned 0.12% of Krystal Biotech worth $182,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 23.07% of the company’s stock.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Featured Story: Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.